Wednesday’s selling carried into Thursday as investors continued to take a risk-off approach to markets following the Federal Reserve’s latest policy announcement.
The central bank issued its third jumbo-sized rate increase yesterday and set expectations that it will continue to hike rates over its next few meetings. However, the Fed is not alone in its aggressive stance. Several global central banks have increased their benchmark rates this week in an ongoing effort to tame inflation, including the Bank of England and Switzerland’s National Bank, which earlier today issued 50 basis point and 75 basis point rate hikes, respectively. (A basis point is one one-hundredth of a percentage point.)
“Global equities are struggling as the world anticipates surging rates will trigger a much sooner and possibly severe global recession,” says Edward Moya, senior market strategist at currency data provider OANDA. “Most of these rate hikes around the world are not done yet which means the race to restrictive territory won’t be over until closer to the end of the year.”
The reaction here at home was a selloff in bond prices, which sent yields on government notes spiking. The 10-year Treasury yield surged 19.2 basis points to 3.704% – its highest level since early 2011 – while the 2-year Treasury yield spiked 12.1 basis points to 4.116%, its loftiest perch since late 2007.
As for stocks, the tech-heavy Nasdaq Composite slumped 1.4% to 11,066, while the S&P 500 Index (-0.8% to 3,757) and the Dow Jones Industrial Average (-0.4% at 30,076) suffered more modest losses.
Other news in the stock market today:
The small-cap Russell 2000 spiraled 2.2% to 1,722.
U.S. crude futures rose 0.7% to finish at $83.49 per barrel.
Gold futures added 0.3% to end at $1,681.10 an ounce.
Bitcoin added 1.7% to $19,322.51. (Bitcoin trades 24 hours a day; prices reported here are as of 4 p.m.)
Eli Lilly (LLY) jumped 4.9% after UBS Global Research analyst Colin Bristow upgraded the healthcare stock to Buy from Neutral. The analyst says following positive data for the company’s SURMOUNT-1 obesity drug and Food and Drug Administration (FDA) approval for its diabetes treatment, T2DM, “we now view LLY as being the most attractive name in our large-cap coverage, with the greatest potential upside to numbers.”
KB Home (KBH) fell 5.1% after just missing analysts’ consensus top-line estimate for its fiscal third quarter. The homebuilder reported earnings of $2.86 per share, more than expected, but revenue of $1.84 billion fell short. Sector peer Lennar (LEN) also unveiled its quarterly results, reporting higher-than-expected fiscal Q3 earnings of $5.03 per share on inline revenue of $8.9 billion. LEN stock rose 2.0% on the day.
Choppy Trading Continues, Consider Defensive ETFs
This is a challenging time for investors, and it’s not likely to get any easier in the near term. “The markets are likely to remain very choppy and range-bound for the foreseeable future in our view because they now have to determine the timing and potential depth of recession ahead plus ongoing inflationary pressures overhead,” says Dan Wantrobski, technical strategist and associate director of research at Janney. He adds that investor sentiment is likely to erode even further as the midterm elections near, and he anticipates a choppy path for stocks in the weeks ahead.